Evidence map›Paper›PMID 42884079›Full record

ReviewInternational journal of molecular sciences2026

Targeting the Microbiota-Metabolism-Immunity Axis: Active Components of Traditional Chinese Medicine in Colitis-Associated Colorectal Cancer.

Qiuying Chen, Hanyi Zhang, Lei Fu, Feifei Liu, Qi Yang, Guangfa Zhang, Yaozhong Huang, Yanxi Yang, Chun Yao, Yitao Wang and 2 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qiuying ChenEngineering Research Center of Innovative Drug of Traditional Chinese and Zhuang Yao Medicine, Ministry of Education, Guangxi University of Chinese Medicine, Nanning 530200, China.
Hanyi ZhangEngineering Research Center of Innovative Drug of Traditional Chinese and Zhuang Yao Medicine, Ministry of Education, Guangxi University of Chinese Medicine, Nanning 530200, China.
Lei FuEngineering Research Center of Innovative Drug of Traditional Chinese and Zhuang Yao Medicine, Ministry of Education, Guangxi University of Chinese Medicine, Nanning 530200, China.
Feifei LiuEngineering Research Center of Innovative Drug of Traditional Chinese and Zhuang Yao Medicine, Ministry of Education, Guangxi University of Chinese Medicine, Nanning 530200, China.
Qi YangInstitute of Traditional Chinese and Zhuang-Yao Ethnic Medicine, Guangxi University of Chinese Medicine, Nanning 530200, China.ORCID 0009-0000-2422-8040
Guangfa ZhangEngineering Research Center of Innovative Drug of Traditional Chinese and Zhuang Yao Medicine, Ministry of Education, Guangxi University of Chinese Medicine, Nanning 530200, China.
Yaozhong HuangEngineering Research Center of Innovative Drug of Traditional Chinese and Zhuang Yao Medicine, Ministry of Education, Guangxi University of Chinese Medicine, Nanning 530200, China.
Yanxi YangEngineering Research Center of Innovative Drug of Traditional Chinese and Zhuang Yao Medicine, Ministry of Education, Guangxi University of Chinese Medicine, Nanning 530200, China.
Chun YaoEngineering Research Center of Innovative Drug of Traditional Chinese and Zhuang Yao Medicine, Ministry of Education, Guangxi University of Chinese Medicine, Nanning 530200, China.
Yitao WangFoshan Joint Key Laboratory for the Research and Development and Industrialization of Chinese Medicinal Formulations, Guangdong Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Foshan 528000, China.
Zhengcai DuInstitute of Traditional Chinese and Zhuang-Yao Ethnic Medicine, Guangxi University of Chinese Medicine, Nanning 530200, China.
Hua LuoEngineering Research Center of Innovative Drug of Traditional Chinese and Zhuang Yao Medicine, Ministry of Education, Guangxi University of Chinese Medicine, Nanning 530200, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colitis-associated colorectal cancer (CAC) develops in the setting of long-standing intestinal inflammation and remains a major complication of inflammatory bowel disease (IBD). Although effective control of inflammation may reduce cancer risk, approaches that specifically prevent the progression from chronic colitis to neoplasia remain limited. Disruption of the gut microbiota-metabolism-immunity axis is increasingly implicated in this process, as microbial dysbiosis and altered metabolite production can compromise epithelial barrier integrity, sustain inflammatory signaling, and disturb mucosal immune homeostasis. This review examines how active components derived from traditional Chinese medicine (TCM), particularly flavonoids, alkaloids, saponins, and polysaccharides, influence this interconnected network in CAC-related models. Rather than treating these constituents as a single group, we compare the mechanistic patterns and evidence base associated with each class. Flavonoids and alkaloids have been studied mainly in relation to inflammatory signaling and epithelial barrier protection, whereas saponins are more often linked to regulation of the immune microenvironment. Polysaccharides have been studied most frequently in relation to microbiota remodeling, short-chain fatty acid production, and mucosal immune balance. These distinctions are not absolute, and substantial overlap exists across component classes. Moreover, most evidence is derived from animal or cell-based studies, with marked variation in experimental models, compound characterizations, dosing, and outcome assessments. The microbiota-metabolism-immunity axis provides a coherent framework for interpreting the multi-level actions of TCM-derived components, but their causal mechanisms and clinical relevance to human CAC require further validation.

Indexed as

ColitisColitis-Associated NeoplasmsColorectal NeoplasmsDrugs, Chinese HerbalGastrointestinal MicrobiomeMedicine, Chinese TraditionalAnimalsHumansIntestinal Barrier FunctionDrugs, Chinese Herbalcolitis-associated colorectal cancergut microbiotaimmune regulationshort-chain fatty acidstraditional Chinese medicine

Identifiers

PMID42884079
PMCPMC13665006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.